Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the Company will ...
News, features, and commentary about cancer-related issues ...
The FDA has released draft guidance that aims to clear up how drug developers can use alternative testing – but that doesn’t mean animal testing in the US is over.